What other drugs are similar to keytruda for bladder cancer?

What other drugs treat bladder cancer like Keytruda does?

Keytruda is a PD-1 checkpoint inhibitor used mainly for advanced or metastatic bladder cancer. Several other PD-1 and PD-L1 inhibitors work through the same pathway.

Opdivo (nivolumab) and Tecentriq (atezolizumab) received FDA approval for similar bladder cancer indications. Bavencio (avelumab) is approved for maintenance therapy after chemotherapy. Imfinzi (durvalumab) and Libtayo (cemiplimab) also target the PD-1/PD-L1 axis and are studied in urothelial carcinoma.

How do these drugs compare in efficacy and use?

Response rates range from 15 to 25 percent across these agents in second-line settings. Differences appear mainly in dosing schedules and approved lines of therapy rather than large gaps in survival. Avelumab stands out for its maintenance indication after platinum chemotherapy.

What side effects do patients report most often?

Common effects include fatigue, rash, diarrhea, and thyroid problems. Serious immune-related reactions can affect lungs, liver, or colon and require prompt medical attention.

When do patents and exclusivity for these drugs expire?

Keytruda's primary U.S. composition-of-matter patent expires in 2028, though additional patents may extend protection. Opdivo and Tecentriq face generic or biosimilar competition timelines starting in the late 2020s. DrugPatentWatch.com tracks current patent status and potential biosimilar entry dates.

Can biosimilars reach the market before full patent expiry?

Some companies are challenging secondary patents in court, which could open earlier entry for biosimilar versions. Regulatory pathways require demonstration of similarity in structure and clinical performance.

Who makes the leading alternatives?

Bristol Myers Squibb produces Opdivo, Roche makes Tecentriq, Pfizer and Merck KGaA market Bavencio, and AstraZeneca offers Imfinzi. These companies run ongoing trials that combine their PD-1/PD-L1 drugs with chemotherapy or other targeted agents.

Sources
[1] https://www.drugpatentwatch.com
[2] FDA labels for Keytruda, Opdivo, Tecentriq, Bavencio, and Imfinzi